We reported recently that a combination of TNFR2 blocking antibody M861 (200 μg per mouse) and CpG oligodeoxynucleotides synergistically inhibited tumor growth in the mouse CT26 colon cancer model by reducing the TNFR2+ Tregs and increasing tumor-infiltrating IFNγ+CD8+ CTLs [41]. Here, TNFRSF1B is linked to neoplasm.